Dr Nathan discusses the trajectory of IPF management. How do you envision these investigational agents potentially being implemented into future treatment paradigms for idiopathic pulmonary fibrosis ...

Steven Nathan, MD, discusses breakthrough treatments for idiopathic pulmonary fibrosis. There are several agents with new mechanisms of action in the pipeline for idiopathic pulmonary fibrosis (IPF).

BECHTELSVILLE, Pennsylvania (WPVI) -- Most of us take breathing for granted. But with pulmonary fibrosis, patients lose that despite the best medical efforts. That outcome is on the verge of change.

In a small pilot study, researchers from North Carolina State University have demonstrated a rapid, simple way to generate large numbers of lung stem cells for use in disease treatment. This method of ...

US-based biopharmaceutical company Rein Therapeutics has dosed the first subject in a Phase II trial of LTI-03, its lead asset for treating idiopathic pulmonary fibrosis (IPF). The double-blind, ...

Phase 2a data show zero cough and 60% lower treatment-related diarrhea than placebo despite higher nintedanib use in the active arm – suggesting ...

PureTech to showcase deupirfenidone programme at American Thoracic Society International Conference from May 15-20, 2026: Boston Friday, May 15, 2026, 18:00 Hrs [IST] PureTech Hea ...

BASEL, Switzerland--(BUSINESS WIRE)--Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, ...

IPF is a rare, progressive and fatal lung disease with a median survival of 2-5 years. 1 Pirfenidone is one of only two drugs approved to treat IPF, and for those patients able to tolerate treatment, ...

LTI-03 is designed to protect and restore the function of the oxygen uptake cells and control lung fibrosis. Credit: SewCreamStudio / Shutterstock. US-based biopharmaceutical company Rein Therapeutics ...